

Second-Party Opinion

Orexo Social Financing Framework



Evaluation Summary

Sustainalytics is of the opinion that the Orexo Social Financing Framework is aligned with the four core components of the Social Bond Principles 2023 and the Social Loan Principles 2023. This assessment is based on the following:



USE OF PROCEEDS The eligible category for the use of proceeds, Access to Essential Services – Healthcare, is aligned with those recognized by the Social Bond Principles and Social Loan Principles that seek to achieve positive socio-economic outcomes for target populations. Sustainalytics considers that investments in the eligible category will lead to positive social impacts and advance the UN Sustainable Development Goals, specifically SDG 3.



PROJECT EVALUATION AND SELECTION Orexo’s Social Financing Committee, which is a subgroup of Orexo’s sustainability committee, will be responsible for the project evaluation and selection process. Orexo has processes in place to identify and mitigate common environmental and social risks potentially associated with the eligible project. Sustainalytics considers the project selection process to be in line with market practice.



MANAGEMENT OF PROCEEDS Orexo’s Finance Department will be responsible for the management and allocation of proceeds and will track the proceeds through an earmarked account. Orexo intends to allocate proceeds within 36 months of issuance. Pending full allocation, proceeds will be placed in a liquidity reserve. This is in line with market practice.



REPORTING Orexo commits to report on allocation of proceeds on its website on an annual basis until full allocation. In addition, Orexo intends to report on relevant impact metrics. Sustainalytics views Orexo’s allocation and impact reporting as aligned with market practice.

Evaluation Date	February 16, 2024
Issuer Location	Uppsala, Sweden

Report Sections

Introduction.....	2
Sustainalytics’ Opinion.....	3

For inquiries, contact the Sustainable Corporate Solutions project team:

Vijay Wilfred (Mumbai)
Project Manager
vijay.wilfred@sustainalytics.com

Javier Frisancho Salinas (Amsterdam)
Project Support

Poonam Tarekar (Mumbai)
Project Support

Kibii Sisulu (London)
Client Relations
susfinance.emea@sustainalytics.com
(+44) 20 3880 0193

Introduction

Orexo AB (“Orexo” or the “Company”) is a pharmaceutical company engaged in the development of pharmaceuticals and digital therapies for substance use disorders and related mental health issues. The Company is headquartered in Uppsala, Sweden, and has commercial operations in the United States.¹

Orexo has developed the Orexo Social Financing Framework dated February 2024 (the “Framework”), under which it intends to issue social bonds and obtain social loans, including multi-tranche loans and revolving credit facilities, and use the proceeds to finance and refinance, in whole or in part, future projects aimed at improving access to healthcare services for the treatment of substance use disorders and other related mental health issues, which are expected to deliver positive social impacts in the US and Sweden. The Framework defines eligibility criteria in one area:

1. Access to Essential Services - Healthcare

Orexo engaged Sustainalytics to review the Framework and provide a Second-Party Opinion on the Framework’s social credentials and its alignment with the Social Bond Principles 2023 (SBP)² and Social Loan Principles 2023 (SLP).³ The Framework will be published in a separate document.⁴

Scope of work and limitations of Sustainalytics’ Second-Party Opinion

Sustainalytics’ Second-Party Opinion reflects Sustainalytics’ independent⁵ opinion on the alignment of the reviewed Framework with current market standards and the extent to which the eligible project categories are credible and impactful.

As part of the Second-Party Opinion, Sustainalytics assessed the following:

- The Framework’s alignment with the Social Bond Principles 2023, as administered by ICMA, and the Social Loan Principles 2023, as administered by LMA, APLMA and LSTA;
- The credibility and anticipated positive impacts of the use of proceeds; and
- The alignment of the issuer’s sustainability strategy and performance and sustainability risk management in relation to the use of proceeds.

For the use of proceeds assessment, Sustainalytics relied on its internal taxonomy, version 1.15, which is informed by market practice and Sustainalytics expertise as an ESG research provider.

As part of this engagement, Sustainalytics held conversations with various members of Orexo’s management team to understand the sustainability impact of their business processes and planned use of proceeds, as well as management of proceeds and reporting aspects of the Framework. Orexo representatives have confirmed (1) they understand it is the sole responsibility of Orexo to ensure that the information provided is complete, accurate and up to date; (2) that they have provided Sustainalytics with all relevant information and (3) that any provided material information has been duly disclosed in a timely manner. Sustainalytics also reviewed relevant public documents and non-public information.

This document contains Sustainalytics’ opinion of the Framework and should be read in conjunction with that Framework.

Any update of the present Second-Party Opinion will be conducted according to the agreed engagement conditions between Sustainalytics and Orexo.

Sustainalytics’ Second-Party Opinion, while reflecting on the alignment of the Framework with market standards, is no guarantee of alignment nor warrants any alignment with future versions of relevant market standards. Furthermore, Sustainalytics’ Second-Party Opinion addresses the anticipated impacts of eligible projects expected to be financed with bond and loan proceeds but does not measure the actual impact. The

¹ Orexo AB, “Annual and Sustainability Report”, (2022), at: https://orexo.com/media/153fx341/orexo_annual-and-sustainability-report-2022.pdf

² The Social Bond Principles are administered by the International Capital Market Association and are available at <https://www.icmagroup.org/sustainable-finance/the-principles-guidelines-and-handbooks/>

³ The Social Loan Principles are administered by the Loan Market Association, Asia Pacific Loan Market Association and Loan Syndications & Trading Association and are available at <https://www.lsta.org/content/social-loan-principles-slp/>

⁴ The Orexo Social Financing Framework is available on Orexo AB’s website at: <https://orexo.com/investors/>

⁵ When operating multiple lines of business that serve a variety of client types, objective research is a cornerstone of Sustainalytics and ensuring analyst independence is paramount to producing objective, actionable research. Sustainalytics has therefore put in place a robust conflict management framework that specifically addresses the need for analyst independence, consistency of process, structural separation of commercial and research (and engagement) teams, data protection and systems separation. Last but not the least, analyst compensation is not directly tied to specific commercial outcomes. One of Sustainalytics’ hallmarks is integrity, another is transparency.

measurement and reporting of the impact achieved through projects financed under the Framework is the responsibility of the Framework owner.

In addition, the Second-Party Opinion opines on the potential allocation of proceeds but does not guarantee the realised allocation of the bond and loan proceeds towards eligible activities.

No information provided by Sustainalytics under the present Second-Party Opinion shall be considered as being a statement, representation, warrant or argument, either in favour or against, the truthfulness, reliability or completeness of any facts or statements and related surrounding circumstances that Orexo has made available to Sustainalytics for the purpose of this SPO.

Sustainalytics' Opinion

Section 1: Sustainalytics' Opinion on the Orexo Social Financing Framework

Sustainalytics is of the opinion that the Orexo Social Financing Framework is credible and impactful, and aligns with the four core components of the SBP and SLP. Sustainalytics highlights the following elements of the Framework:

- Use of Proceeds:
 - The eligible category, Access to Essential Services - Healthcare, is aligned with those recognized by the SBP and SLP.
 - Sustainalytics notes that refinancing under the Framework will have a look-back period of 36 months.
 - Under the Access to Essential Services – Healthcare category, Orexo may finance or refinance the following in Sweden and the US:
 - Development, manufacturing and commercialization of: i) OX124, a high-dose naloxone-based opioid overdose rescue medication; and ii) OX125, a high-dose nalmefene-based opioid overdose rescue medication.^{6,7} Sustainalytics notes the high need of opioid medications and treatments as they have the highest contribution to severe drug-related harm, including fatal overdoses, with 60 million people globally engaged in non-medical opioid use in 2021.⁸ For more information, please refer to section 3. Sustainalytics also notes that the development of Orexo's medicines is still in progress and is pending approval from the FDA.⁹ Therefore, affordability mechanisms have not been implemented as of now. Orexo has confirmed to Sustainalytics that it intends to put such mechanisms in place after FDA approval. For OX124, Orexo has confirmed that it will have financial support programmes and will offer the product free of charge to patients whose income is up to 300% of the US federal poverty level.¹⁰ Regarding pricing, Orexo has confirmed that the majority of patients will have access to insurance coverage and that Orexo will offer co-payment support, for which the complete details will be defined once the product receives approval from the FDA. Under commercialization activities, Orexo has confirmed that these refer to communication material and promotion to build product awareness to ensure that patients know how to use the medication, develop storage carry bags to

⁶ Naloxone and nalmefene are novel reversal drugs. The FDA approved the first over-the-counter naloxone nasal spray in March 2023 and the first nalmefene hydrochloride nasal spray in May 2023.

FDA, "Information about Naloxone and Nalmefene", at: <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/information-about-naloxone-and-nalmefene>

⁷ WHO, "World Health Organization Model List of Essential Medicines 23rd list", (2023), at: <https://iris.who.int/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1>

⁸ UN Office on Drugs and Crime, "World Drug Report 2023", (2023), at: https://www.unodc.org/res/WDR-2023/WDR23_Exsum_fin_DP.pdf

⁹ In September 2023, Orexo submitted a new drug application (NDA) for OX124 to the US Food and Drug Administration (FDA) and expects to receive approval by July 2024, while the first phase of the drug development process – Discovery and Development – is in its final phases for OX125.

FDA, "The Drug Development Process", at: <https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process>

Orexo, "Products under Development", at: <https://orexo.com/solutions/products-under-development/>

¹⁰ HealthCare.gov, "Federal poverty level (FPL)", at: <https://www.healthcare.gov/glossary/federal-poverty-level-fpl/>

- enable patients to bring the product with them discretely, and educate them about the risks related to misusing synthetic opioids.
- Collaboration projects with key stakeholders, including local healthcare providers, to make opioid use disorder (OUD) treatment solutions available to vulnerable patients. Orexo has confirmed that it will work with stakeholders at the federal and state levels to ensure that more financially vulnerable individuals have access to OUD drugs regardless of the manufacturer. Under these collaborations, Orexo will offer maintenance treatments and digital mental health programmes that include education and counselling through reimbursements. Orexo has confirmed that it will offer financial support for these programmes only to patients whose income is up to 300% of the federal poverty level.
 - Development of OX640 for the treatment of life-threatening allergic reactions. OX640 is a nasal epinephrine rescue medication. Sustainalytics notes that epinephrine is included in the WHO Model List of Essential Medicines 2023.¹¹ OX640 is in the clinical research phase and Orexo aims to offer product stability in extreme temperatures, as opposed to existing products on the market, which have to be stored at room temperature, limiting their use for people living under conditions or in regions where temperatures cannot be controlled.¹² Regarding affordability, Orexo has confirmed to Sustainalytics that it will rely on internal processes similar to the ones developed for OX124 and OX125.
 - Development of other projects based on the amorphOX platform, with the aim of improving stability and accessibility of medications. AmorphOX is a nasal powder technology aimed at extending the shelf life of medications. Orexo has confirmed that these expenditures will be directed to testing the technology on new medications, not including OX124, OX125 and OX640. Sustainalytics notes that this technology is novel and not currently available in the market. Orexo has clarified to Sustainalytics that it will be working with external partners to apply the amorphOX drug delivery platform on other drugs and vaccines. Sustainalytics notes that Orexo has not specified which drugs and vaccines will be financed under this expenditure. Nevertheless, Orexo has emphasized that the goal of this expenditure is to develop improved medicines that meet major medical needs. Sustainalytics encourages Orexo to report on financed medicines and vaccines under this expenditure and social impacts achieved.
 - Sustainalytics considers these expenditures to be socially impactful.
- Project Evaluation and Selection:
 - Orexo’s Social Financing Committee (the “Committee”), which is a subgroup of Orexo’s sustainability committee (OSC) will be responsible for the evaluation and selection of eligible projects in line with the Framework’s eligibility criteria. The Committee and the OSC are led by the Senior Vice President and the Head of Operations of the Company. In addition to them, the Committee and the OSC include the Quality and Safety Health and Environment manager, the Investors Relations and Communications Director, the Sustainability manager, the Senior Director from Commercial Operations and the Human Resources manager.
 - Orexo has communicated to Sustainalytics that OSC will undertake continuous monitoring of the environmental and social risks associated with the projects financed under the Framework. For additional details, please refer to Section 2.
 - Based on the establishment of the Committee and the presence of risk management systems, Sustainalytics considers this process to be in line with market practice.
 - Management of Proceeds:
 - Orexo’s Finance Department will be responsible for the management and allocation of proceeds and will track the proceeds through an earmarked account.
 - Orexo has communicated to Sustainalytics that instruments issued under the Framework may include multi-tranche bonds and loan facilities. The Company intends to label only those

¹¹ WHO, “World Health Organization (WHO) Model List of Essential Medicines 23rd list”, (2023), at: <https://iris.who.int/bitstream/handle/10665/371090/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1>

¹² Orexo, “Products under Development”, at: <https://orexo.com/solutions/products-under-development/>

- tranches of such facilities whose proceeds will be allocated according to the eligibility criteria in the Framework.
- Orexo intends to allocate proceeds within 36 months of issuance. Pending full allocation, unallocated proceeds will be placed in the liquidity reserve.
 - Based on the use of a tracking system and the disclosure of the temporary use of proceeds, Sustainalytics considers this process to be in line with market practice.
- Reporting:
 - Orexo will report on the allocation of proceeds on its website on an annual basis until full allocation and on a timely basis, in case of any material development. For revolving credit facilities, the Company has confirmed that reporting will continue until the maturity of such facilities.
 - Allocation reporting will include a description of the eligible projects, the amount of proceeds to be allocated to eligible projects, the amount of unallocated proceeds and the share of financing versus refinancing.
 - Orexo also intends to report on impacts, which may include relevant impact indicators, such as: i) total number of patients and, to the extent possible, the number of vulnerable patients reached by Orexo's OUD treatment solutions related to the eligible projects; ii) number of products offering patient assistant programmes and reach of these programmes; and iii) number of medicines based on the amorphOX drug delivery platform.
 - Based on the commitment to allocation and impact reporting, Sustainalytics considers this process to be in line with market practice.

Alignment with Social Bond Principles 2023 and Social Loan Principles 2023

Sustainalytics has determined that the Orexo Social Financing Framework aligns with the four core components of the SBP and SLP.

Section 2: Sustainability Strategy of Orexo

Contribution to Orexo's sustainability strategy

Sustainalytics is of the opinion that Orexo has demonstrated a commitment to sustainability by focusing on the following strategic priority areas as part of its sustainability strategy: i) responsible business; ii) access to healthcare; iii) sustainable employees; and iv) environment and climate change.¹³ Orexo's sustainability strategy is informed by its materiality assessment conducted in 2022, through which Orexo identified key material sustainability areas, including responsible manufacturing and transport, increased access to products, responsible procurement and ethical business.¹⁴

Regarding its strategic area of access to healthcare, Orexo intends to support vulnerable patients overcome financial barriers through various programmes and initiatives and strengthen the knowledge of substance use and mental illness.¹⁵ Such support programmes include: i) a patient assistance programme, through which the Company has supported 3,073 patients by providing them with the opioid overdose medication Zubsolv (buprenorphine and naloxone) free of cost for the first six months to individuals whose income level is up to 300% of the federal poverty level; ii) a co-pay assistance programme benefitting nearly 1.3 million patients without health insurance coverage, in collaboration with external entities; and iii) a tablet voucher programme, through which the Company distributed 225,645 tablet vouchers to patients.¹⁶ In 2019, the Company developed MODIA, a digital therapy for opioid use disorder, which provided psychosocial support to more than 3,000 patients, including in rural areas.¹⁷ Orexo also provides evidence-based digital therapies, Vorvida and Deprexis, for alcohol management and depression, respectively. Orexo has also collaborated with the US Department of Veteran Affairs to provide access to its digital therapy, Deprexis, for approximately 15 million veterans and their families. In addition, through its partnership with the Wayside Recovery Center in Minneapolis, Orexo received a grant for a project that enables access to its digital therapies, Vorvida and

¹³ Orexo, "Sustainability: What we do matters", at: <https://orexo.com/sustainability/focus-areas/>

¹⁴ Orexo shared the Draft Sustainability Report 2023 with Sustainalytics confidentially.

¹⁵ Ibid.

¹⁶ Ibid.

¹⁷ Orexo, "Sustainability Report", (2022), at: <https://orexo.com/media/g1emd5kq/orexo-sustainability-report-2022.pdf>

Deprexis, for 60 pregnant women with mental health and substance use disorder needs.¹⁸ In 2023, Orexo achieved its target of covering 100% of its products with patient assistance programmes.¹⁹

Sustainalytics is of the opinion that the Orexo Social Financing Framework is aligned with the Company's overall sustainability strategy and initiatives and will further the Company's action on its key social priorities.

Approach to managing social and environmental risks associated with the projects

Sustainalytics recognizes that the net proceeds from the Framework will be directed towards eligible projects that are expected to have positive social impacts. However, Sustainalytics is aware that such eligible projects could also lead to negative environmental and social outcomes. Some key environmental and social risks possibly associated with the eligible projects could include issues related to product governance, business ethics, bribery and corruption, and access to basic services.

Sustainalytics is of the opinion that Orexo is able to manage or mitigate potential risks through implementation of the following:

- Orexo addresses risks related to product governance through its Business Compliance and Ethics Code, which mandates compliance with all applicable laws and regulations, the Declaration of Helsinki and recognized international safety standards.²⁰ The code commits the Company to monitor the safety and efficacy of its products in the market and to identify any change to their benefit-risk balance, including ensuring that all pharmaceutical products meet the quality requirements at all stages and are suitable for the intended use by patients. Furthermore, the code requires providing accurate product information supported by scientific evidence, including information on fair balance about the products' benefits and risks, in addition to complying with applicable ethical standards.²¹ The code also commits Orexo to perform animal testing only after consideration to replace animals, to reduce the numbers of animals used, or to refine procedures to minimize distress and to respect the welfare of animals used. Also, Orexo's U.S. Code of Business Conduct and Ethics outlines the Company's commitment towards providing accurate and non-misleading information about the approved uses of all its products, including relevant safety information. The Company's U.S. Code of Business Conduct and Ethics also mandates the Company to comply with applicable laws, regulations and industry standards, including the US Federal Food, Drug, and Cosmetic Act (FDCA),²² PhRMA's Code on Interactions With Health Care Professionals²³ and the PhAMA Code of Pharmaceutical Marketing Practices.^{24,25}
- Regarding risks pertaining to business ethics, bribery and corruption, the Company's Business Compliance and Ethics Code applies to all employees, consultants, temporary staff and subsidiaries. The code also commits Orexo and its employees to comply with all applicable laws and regulations, including in relation to preventing unethical behaviour, such as corruption, bribery, conflicts of interest and fraud.²⁶ Orexo's US Code of Business Conduct and Ethics also outlines requirements for all employees to ensure adherence to anti-bribery and anti-corruption laws, including the US Foreign Corrupt Practices Act (FCPA).^{27,28}
- To address risks related to access to basic services, Orexo's U.S. Code of Business Conduct and Ethics commits the Company's to comply with all applicable antitrust and competition laws,

¹⁸ Ibid.

¹⁹ Orexo shared the Draft Sustainability Report 2023 with Sustainalytics confidentially.

²⁰ Orexo, "Business Compliance and Ethics Code", (2020), at: <https://orexo.com/media/ykqqs44/orexo-business-compliance-and-ethics-code.pdf>

²¹ Ibid.

²² US Food and Drug Administration, "Federal Food, Drug, and Cosmetic Act (FD&C Act)", (2018), at: <https://www.fda.gov/regulatory-information/laws-enforced-fda/federal-food-drug-and-cosmetic-act-fdc-act>

²³ Pharmaceutical Research and Manufacturers of America, "Code on Interactions With Health Care Professionals", (2021), at: <https://phrma.org/en/resource-center/Topics/STEM/Code-on-Interactions-with-Health-Care-Professionals>

²⁴ International Federation of Pharmaceutical Manufacturers and Association, "PhAMA Code of Pharmaceutical Marketing Practices", at: <https://www.ifpma.org/wp-content/uploads/2022/12/PhAMA-Code-21st-Edition-1.pdf>

²⁵ Orexo, "U.S. Code of Business Conduct and Ethics", at: <https://orexo.com/media/3v2gjy2h/cl-004-07-orexo-us-code-of-business-conduct-ethics-aug-2022.pdf>

²⁶ Ibid.

²⁷ Ibid.

²⁸ US Department of Justice, "Foreign Corrupt Practices Act", (2023), at: <https://www.justice.gov/criminal/criminal-fraud/foreign-corrupt-practices-act>

prohibiting agreements with competitors, suppliers and customers to fix prices of products or restrain trade.²⁹

Based on these policies, standards and assessments, Sustainalytics is of the opinion that Orexo has implemented adequate measures and is well positioned to manage and mitigate environmental and social risks commonly associated with the eligible categories.

Section 3: Impact of Use of Proceeds

The use of proceeds category is aligned with those recognized by the SBP and SLP and is relevant in the local context.

Importance of equitable access to opioid treatment and medication in the US

As at 2021, the estimated number of drug users in the world was 296 million people, which represents a 23% increase from 2011.³⁰ Opioids is the group of substances with the highest contribution to severe drug-related harm, including fatal overdoses, with 60 million people engaged in non-medical opioid use in 2021. Opioids are also the leading cause of deaths in fatal overdoses, accounting for nearly 70% of the 128,000 deaths attributed to drug use disorders worldwide in 2019.³¹

In the US, 35.2 million people aged 12 or older had a drug use disorder in 2022³² and the number of deaths caused by synthetic opioids excluding methadone overdose increased 103-fold between 1999 and 2023.³³ In 2022, there were more than 50,000 overdose deaths in the US, 81.8% of which involving at least one opioid, with illegally made fentanyl being the most commonly involved opioids.³⁴ Additionally, only 6.4% of those who died of an overdose were receiving treatment and 64.7% were reported to have had at least one potential opportunity for intervention.³⁵ According to the Centers for Disease Control and Prevention, expanding access to evidence-based treatments, such as medication-assisted therapy and use of naloxone can reverse the effects of an opioid overdose when administered in time.³⁶

In 2023, the Substance Abuse and Mental Health Services Administration (SAMHSA) of the US Department of Health and Human Services received USD 7.5 billion from the US government to improve access to integrated care, increase the behavioural health workforce and increase access to medications for OUDs.^{37,38} SAMHSA's 2023–2026 Strategic Plan³⁹ has as first priority preventing substance use and overdose, and includes the following goals: i) reduce and prevent substance use and misuse; ii) prevent overdose deaths by supporting efforts to transform systems and services that increase access to and use of harm reduction approaches and effective treatments, increasing the use of medications for OUDs and supporting evidence-based interventions, such as opioid education, naloxone distribution to reverse overdoses and syringe service programmes to reduce infectious diseases spread; and iii) advance recovery by expanding resources for families and caregivers impacted by overdoses.

Sustainalytics is of the opinion that Orexo's allocation of proceeds to finance projects that provide OUD-related solutions to the targeted groups is expected to increase equitable access to said solutions, contributing to other efforts and initiatives on opioid use disorders in the US

²⁹ Orexo, "U.S. Code of Business Conduct and Ethics", at: <https://orexo.com/media/3v2gij2h/cl-004-07-orexo-us-code-of-business-conduct-ethics-aug-2022.pdf>

³⁰ UN Office on Drugs and Crime, "World Drug Report 2023", (2023), at: https://www.unodc.org/res/WDR-2023/WDR23_Exsum_fin_DP.pdf

³¹ Ibid.

³² SAMHSA, "Highlights for the 2022 National Survey on Drug Use and Health", at: <https://www.samhsa.gov/data/sites/default/files/reports/rpt42731/2022-nsduh-main-highlights.pdf>

³³ US Department of Health & Human Services, "Trends in U.S. Drug Overdose Deaths (December 1999–June 2023), by Drug Type", at: <https://www.hhs.gov/overdose-prevention/>

³⁴ CDC, "SUDORS Dashboard: Fatal Overdose Data", (2023), at: <https://www.cdc.gov/drugoverdose/fatal/dashboard/index.html>

³⁵ Ibid.

³⁶ CDC, "Reverse Overdose to Prevent Death", at: <https://www.cdc.gov/opioids/overdoseprevention/reverse-od.html>

³⁷ Ibid.

³⁸ SAMHSA, "About Us", at: <https://www.samhsa.gov/about-us>

³⁹ SAMHSA, "Strategic Plan 2023-2026", (2023), at: <https://www.samhsa.gov/sites/default/files/samhsa-strategic-plan.pdf>

Contribution to SDGs

The Sustainable Development Goals were adopted in September 2015 by the United Nations General Assembly and form part of an agenda for achieving sustainable development by 2030. The instruments issued under the Orexo Social Financing Framework are expected to help advance the following SDG and targets:

Use of Proceeds Category	SDG	SDG target
Access to Essential Services	3. Good Health and Wellbeing	3.5 Strengthen the prevention and treatment of substance abuse, including narcotic drug abuse and harmful use of alcohol 3.8 Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all

Conclusion

Orexo has developed the Orexo Social Financing Framework, under which it may issue social bonds or obtain social loans and use the proceeds to finance projects that improve access to healthcare services for the treatment of substance use disorders and other related mental health issues. Sustainalytics considers that the projects funded by the social instrument proceeds are expected to provide positive social impacts.

The Orexo Social Financing Framework outlines a process by which proceeds will be tracked, allocated and managed, and commitments have been made for reporting on the allocation and impacts of the use of proceeds. Sustainalytics considers the Orexo Social Financing Framework to be aligned with the overall sustainability strategy of the Company and that the social use of proceeds category will contribute to the advancement of UN Sustainable Development Goal 3. Additionally, Sustainalytics is of the opinion that Orexo has adequate measures to identify, manage and mitigate environmental and social risks commonly associated with the eligible projects funded by the proceeds.

Based on the above, Sustainalytics is confident that Orexo is well positioned to issue social bonds and that the Orexo Social Financing Framework is robust, transparent and in alignment with the core components of the Social Bond Principles 2023 and Social Loan Principles 2023.

Disclaimer

Copyright ©2024 Sustainalytics. All rights reserved.

The information, methodologies and opinions contained or reflected herein are proprietary of Sustainalytics and/or its third party suppliers (Third Party Data), and may be made available to third parties only in the form and format disclosed by Sustainalytics, or provided that appropriate citation and acknowledgement is ensured. They are provided for informational purposes only and (1) do not constitute an endorsement of any product or project; (2) do not constitute investment advice, financial advice or a prospectus; (3) cannot be interpreted as an offer or indication to buy or sell securities, to select a project or make any kind of business transactions; (4) do not represent an assessment of the issuer's economic performance, financial obligations nor of its creditworthiness; and/or (5) have not and cannot be incorporated into any offering disclosure.

These are based on information made available by the issuer and therefore are not warranted as to their merchantability, completeness, accuracy, up-to-dateness or fitness for a particular purpose. The information and data are provided "as is" and reflect Sustainalytics' opinion at the date of their elaboration and publication. Sustainalytics accepts no liability for damage arising from the use of the information, data or opinions contained herein, in any manner whatsoever, except where explicitly required by law. Any reference to third party names or Third Party Data is for appropriate acknowledgement of their ownership and does not constitute a sponsorship or endorsement by such owner. A list of our third-party data providers and their respective terms of use is available on our website. For more information, visit <http://www.sustainalytics.com/legal-disclaimers>.

The issuer is fully responsible for certifying and ensuring the compliance with its commitments, for their implementation and monitoring.

In case of discrepancies between the English language and translated versions, the English language version shall prevail.

About Sustainalytics, a Morningstar Company

Sustainalytics, a Morningstar Company, is a leading ESG research, ratings and data firm that supports investors around the world with the development and implementation of responsible investment strategies. For more than 30 years, the firm has been at the forefront of developing high-quality, innovative solutions to meet the evolving needs of global investors. Today, Sustainalytics works with hundreds of the world's leading asset managers and pension funds who incorporate ESG and corporate governance information and assessments into their investment processes. Sustainalytics also works with hundreds of companies and their financial intermediaries to help them consider sustainability in policies, practices and capital projects. With 17 offices globally, Sustainalytics has more than 1500 staff members, including more than 500 analysts with varied multidisciplinary expertise across more than 40 industry groups.

For more information, visit www.sustainalytics.com

Or contact us contact@sustainalytics.com

